Recent Quotes (30 days)

You have no recent quotes
chg | %

Pivotal Therapeutics Inc  

(Public, CNSX:PVO)   Watch this stock  
Find more results for PVO
0.0000 (0.00%)
Jul 30 - Close
CNSX real-time data - Disclaimer
Currency in CAD
Range     -
52 week 0.03 - 0.14
Open     -
Vol. 0.00
Mkt cap 4.75M
P/E     -
Div/yield     -
EPS -0.05
Shares 95.01M
Beta     -
Inst. own     -
Jun 1, 2015
Q1 2015 Pivotal Therapeutics Inc Earnings Release

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -776.68% -1755.14%
Operating margin -462.33% -1883.34%
EBITD margin - -1849.58%
Return on average assets -248.75% -256.34%
Return on average equity - -
CDP Score - -


81 Zenway Blvd Unit 10
+1-905-8569797 (Phone)
+1-905-8562177 (Fax)

Website links


Pivotal Therapeutics, Inc. is a Canada-based specialty pharmaceutical company with a focus on cardiovascular disease and overall health. The company’s lead product VASCAZEN is a prescription only medical food formulated to meet the dietary Omega-3 deficient needs of patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosaophexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. Its second product, OMAZEN is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health.

Officers and directors

John S. Gebhardt Independent Chairman of the Board
Age: 67
Rachelle MacSweeney President, Chief Operating Officer, Director
Eugenio G. Bortoluzzi Chief Executive Officer, Chief Financial Officer, Director
James J. Carey Independent Vice Chairman of the Board
George Jackowski Ph.D. Chief Scientific Officer, Director
Giuseppe Simeone Independent Director